[7]
El-Readi, M.Z.; Althubiti, M.A. Cancer nanomedicine: A new era of successful targeted therapy. J. Nanomat., 2019, 2019, 4927312.
[14]
Vhora, I.; Patil, S.; Bhatt, P.; Misra, A. Protein-and peptide-drug conjugates: An emerging drug delivery technology. Adv. In Pro. Chem. And struc. Biology (Basel), 2015, 98, 1-55.
[18]
Kanwal, S. Effect of O-GlcNAcylation on tamoxifen sensitivity in
breast cancer derived MCF-7 cells, Doctoral dissertation, Paris, 2013, pp. 1-204.
[23]
McConkey, B.J.; Sobolev, V.; Edelman, M. The performance of current methods in ligand–protein docking. Curr. Sci., 2002, 83(7), 845-856.
[27]
Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein–ligand docking using GOLD. Protein: Struct., Fun., and Bioinfo., 2003, 52(4), 609-623.
[35]
Edmonds, D.J.; Price, D.A. Oral GLP-1 modulators for the treatment of diabetes. In: Annual Reports in Medicinal Chemistry; Academic Press: Cambridge, 2013; Vol. 48, pp. 119-130.
[148]
Mohanraj, V.; Chen, Y. Nanoparticles- A review. Trop. J. Pharm. Res., 2006, 5, 56-573.
[150]
Bogden, A.E.; Hopedale, M.A.; Moreau, J.P. Treatment of cancer with peptide analog of bombesin, GRP. Litorin or neuromedin. US5217955A, 1993.
[151]
Lori, A.H.; William, S.; Dalton, A.E. HYD1 peptides as anti- cancer agents. US7632814B2, 2009.
[152]
Auricchio, F.; Migliaccio, A. Anti-androgen peptides and uses thereof in cancer therapy. US9919023B2, 2018.
[153]
Thoresen, A.; Sergio, M.S. Novel peptides with anti-tumor activity. W02009014450A1, 2009.
[154]
Figdor, C.G.; Adema, G.J. Melanoma associated peptide analogues and vaccines against melanoma. US8075900B2, 2011.
[155]
Rapraeger, A. Syndecan peptides and polypeptides as inhibitors of cancer. US9034827B2, 2015.
[156]
Hunt, D.F.; Jeffrey, S.; Abelin, J.G. Target peptides for colorectal cancer therapy and diagnostics. US20150328297A1, 2020.
[157]
Wu, H.C.; Chang, D.K.; Chiu, C.Y. Tumor-targeting peptides and uses thereof in tumor diagnosis and treatment. US20100119444, 2013.
[158]
Rudloff, U. J.; Jesse, M.; Henry, W.L. Peptide-based methods for treating pancreatic cancer. US10016480, 2018.
[159]
Nakamura, Y.; Tsunoda, T.; Ohsawa, R. Ect2 peptides and vaccines including the same. US20130095128A1, 2015.
[160]
Wu, H.C.; Chiu, C.Y. Cancer-targeting peptides and uses thereof in cancer therapy. US867407B2, 2018.
[161]
Zeng, M.; Zhang, M.; Wang, X.; Feng, J.; Zhang, G.; Zhong, Q. Tumor-targeting polypeptide and application thereof. US20160355548, 2018.
[162]
Mukherjee, R.; Burman, A.C.; Anu, T. Synthetic peptide analogs for the treatment of cancer. CA002511446A, 2010.
[163]
Fogelman, A.M.; Navab, M. Peptides and peptide mimetics to treat cancer. US12721366, 2010.
[164]
Figdor, C.G.; Adema, GJ. Melanoma associated peptide analogues and vaccines against melanoma. US7846450B2, 2010.
[165]
Kawakami, K.; Kohno, M.; Horibe, T. Selective anticancer chimeric peptide. US20110319336A1, 2013.
[166]
Nishimura, Y.; Yokomine, K.; Tsunoda, T. Foxm1 peptide and medicinal agent comprising the same. US20110195081A1, 2013.
[167]
Wucherpfennig, K.W.; Franz, B.; Kenneth, F. Therapeutic peptides. US20140004112A1, 2016.
[168]
Frank, D. H.; Clayman, G. Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery. US6919425B2, 2005.
[169]
Eisenbach, L.; Tirosh, B.; Bar-Haim, E. Tumor associated antigen peptides and use of same as anti-tumor vaccines. US7960507B2, 2011.
[170]
Tsunoda, T.; Ohsawa, R. Peptide vaccines for cancers expressing tumor-associated antigens. EP2476692A2, 2015.
[171]
Straten, EPT.; Mads, A.H. Survivin-derived peptides and use thereof. EP2092938B1, 2011.
[172]
Kelly, K.; Jones, D. Colon tumor specific binding peptides. US20060058228A1, 2008.
[173]
Cho, CH.; Li, Z. Homing peptide for tumor vasculature. EP2459584B1, 2014.
[174]
Shemesh, R.; Levine, Z.; Toporik, A. Bioactive peptides and methods of using same. US20110177998A1, 2013.
[175]
Demoyen, PL.; Adotevi, O.; Dosset, M. Universal cancer peptides derived from telomerase. W02013135553A, 2013.
[176]
Tsunoda, T.; Ohsawa, R.; Yoshimura, S. C1orf59 peptides and vaccines including the same. US20120003253A1, 2014.
[177]
Hunt, DF.; Shabanowitz, J. Target peptides for ovarian cancer therapy and diagnostics. WO2014093855A1, 2014.
[178]
Hunt, DF.; Shabanowitz, J.; Abelin, J.G.; Cobbold, M.; Penny, S. Target peptides for colorectal cancer therapy and diagnostics. US20210154279A1,
[179]
Tsunoda, T.; Ohsawa, R.; Yoshimura, S. Peptides and vaccines including the same. US20120093845A1, 2015.